Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer. / Garset-Zamani, Martin; Carlander, Amanda F.; Jakobsen, Kathrine K.; Friborg, Jeppe; Kiss, Katalin; Marvig, Rasmus L.; Olsen, Caroline; Nielsen, Finn C.; Andersen, Elo; Grønhøj, Christian; von Buchwald, Christian.
I: International Journal of Cancer, Bind 150, Nr. 7, 2022, s. 1174-1183.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer
AU - Garset-Zamani, Martin
AU - Carlander, Amanda F.
AU - Jakobsen, Kathrine K.
AU - Friborg, Jeppe
AU - Kiss, Katalin
AU - Marvig, Rasmus L.
AU - Olsen, Caroline
AU - Nielsen, Finn C.
AU - Andersen, Elo
AU - Grønhøj, Christian
AU - von Buchwald, Christian
N1 - Publisher Copyright: © 2021 UICC.
PY - 2022
Y1 - 2022
N2 - The increases observed in incidence and survival of oropharyngeal squamous cell carcinoma (OPSCC) have been attributed to human papillomavirus (HPV) infection, but the survival-impact of specific genotypes is poorly understood. We investigated the potential influence of HPV genotypes on survival in HPV-positive (HPV+) OPSCC. All patients with HPV+/p16+ OPSCC and available genotype data within the period 2011 to 2017 in Eastern Denmark were included. Descriptive statistics on clinical and tumor data, as well as overall survival (OS) and recurrence-free survival (RFS) with Cox hazard models and Kaplan-Meier plots were performed. Overall, 769 HPV+/p16+ OPSCC patients were included of which genotype HPV16 accounted for 86% (n = 662). Compared to high-risk non-HPV16 genotypes (HR non-HPV16), HPV16 patients were younger at diagnosis (median years, 60 vs 64), had a higher male to female ratio (3.7:1 vs 2.1:1), and lower performance scores of ≤1 (90%, n = 559, vs 81%, n = 74). Regarding 5-year OS and RFS, no difference was observed between HPV16 and HR non-HPV16 patients. Subgrouping the HR non-HPV16 group into HPV33 (n = 57), HPV35 (n = 26) and “other genotypes” (n = 24) a significantly worse OS in the “other genotypes” group (hazard rate: 2.33, P =.027) was shown. With similar survival results between HPV16 and non-HPV16 genotypes, genotyping in OPSCC is interesting from an epidemiological point of view as well as in vaccination programs, but not a necessary addition in prognostication of HPV+/p16+ OPSCC.
AB - The increases observed in incidence and survival of oropharyngeal squamous cell carcinoma (OPSCC) have been attributed to human papillomavirus (HPV) infection, but the survival-impact of specific genotypes is poorly understood. We investigated the potential influence of HPV genotypes on survival in HPV-positive (HPV+) OPSCC. All patients with HPV+/p16+ OPSCC and available genotype data within the period 2011 to 2017 in Eastern Denmark were included. Descriptive statistics on clinical and tumor data, as well as overall survival (OS) and recurrence-free survival (RFS) with Cox hazard models and Kaplan-Meier plots were performed. Overall, 769 HPV+/p16+ OPSCC patients were included of which genotype HPV16 accounted for 86% (n = 662). Compared to high-risk non-HPV16 genotypes (HR non-HPV16), HPV16 patients were younger at diagnosis (median years, 60 vs 64), had a higher male to female ratio (3.7:1 vs 2.1:1), and lower performance scores of ≤1 (90%, n = 559, vs 81%, n = 74). Regarding 5-year OS and RFS, no difference was observed between HPV16 and HR non-HPV16 patients. Subgrouping the HR non-HPV16 group into HPV33 (n = 57), HPV35 (n = 26) and “other genotypes” (n = 24) a significantly worse OS in the “other genotypes” group (hazard rate: 2.33, P =.027) was shown. With similar survival results between HPV16 and non-HPV16 genotypes, genotyping in OPSCC is interesting from an epidemiological point of view as well as in vaccination programs, but not a necessary addition in prognostication of HPV+/p16+ OPSCC.
U2 - 10.1002/ijc.33893
DO - 10.1002/ijc.33893
M3 - Journal article
C2 - 34894151
AN - SCOPUS:85121579154
VL - 150
SP - 1174
EP - 1183
JO - Acta - Unio Internationalis Contra Cancrum
JF - Acta - Unio Internationalis Contra Cancrum
SN - 0898-6924
IS - 7
ER -
ID: 320053673